Overall, these data obtained from primary FLT3-ITD+ AML patient samples further substantiate that the combination of p300/CBP inhibitors and FLT3 inhibitors concomitantly suppresses both FLT3 signaling and H3K27Ac, demonstrating synergistic antileukemia effects and highlighting considerable promise for the clinical application of such combination therapies. This evidence concerns the gene EP300 and acute myeloid leukemia.